Alx oncology strengthens ip portfolio; announces end of post-grant review period for issued u.s. patent covering alx148

Burlingame, calif., april 05, 2021 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, announces that the post-grant review period for granted u.s. patent no. 10,696,730 ended on march 30, 2021. this patent covers the lead product candidate alx148, a next generation cd47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“sirp“) cd47-binding domain fused with an inactivated, proprietary fc domain. the u.s. patent is not expected to expire before august 5, 2036, excluding patent term adjustments or extensions.
ALXO Ratings Summary
ALXO Quant Ranking